Sinovac Biotech Ltd
SVA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001084201
No open-market purchases or sales by Sinovac Biotech Ltd insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $224.9M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Sinovac Biotech Ltd as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 30
- +1 vs. Q2 2023
- Shares held
- 11.9M
- +78.2K (+0.7%) vs. Q2 2023
- Total value
- $43.2M
- +$37.6M (+674.9%) vs. Q2 2023
- New holders
- 1
- 2 more added
- Sold out
- 0
- 1 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SVA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 28 | $224.9M |
| Q1 2026 | 28 | $40.4M |
| Q4 2025 | 28 | $225.3M |
| Q3 2025 | 27 | $225.0M |
| Q2 2025 | 28 | $375.4M |
| Q1 2025 | 3 | $336.0M |
| Q4 2024 | 4 | $336.0M |
| Q3 2024 | 9 | $418.4M |
| Q2 2024 | 26 | $79.6M |
| Q1 2024 | 26 | $80.7M |
| Q4 2023 | 8 | $342.0M |
| Q3 2023 | 30 | $43.2M |
| Q2 2023 | 29 | $5.58M |
| Q1 2023 | 4 | $957.4M |
| Q4 2022 | 9 | $380.2M |
| Q3 2022 | 30 | $44.0M |
| Q2 2022 | 31 | $44.0M |
| Q1 2022 | 11 | $41.6M |
| Q4 2021 | 29 | $44.9M |
| Q3 2021 | 29 | $44.9M |
| Q2 2021 | 28 | $44.9M |
| Q1 2021 | 29 | $44.8M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Sinovac Biotech Ltd; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 5,900,000 | $38.2M | 4.72% | 00.0% | Unchanged |
| Neumann Advisory Hong Kong Ltd | 315,586 | $2.04M | 0.82% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 2,375,841 | $1.54M | 0.00% | 00.0% | Unchanged |
| State Street Corp | 160,875 | $1.04M | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 27,717 | $179.3K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 16,430 | $106.3K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 9,095 | $58.8K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 6,879 | $44.5K | 0.00% | +2,313+50.7% | Added |
| JPMorgan Chase & Co | 3,000 | $19.4K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 1,661 | $10.7K | 0.00% | 00.0% | Unchanged |
| Yorktown Management & Research Co Inc | 149,786 | $4.49K | 0.01% | +74,893+100.0% | Added |
| Group One Trading, L.P. | 412 | $2.67K | 0.00% | 00.0% | Unchanged |
| Northwestern Mutual Wealth Management Co | 102 | $660 | 0.00% | −6−5.6% | Reduced |
| Horizon Investments, LLC | 52 | $336 | 0.00% | 00.0% | Unchanged |
| Skandinaviska Enskilda Banken AB (publ) | 40,000 | $0 | 0.00% | 00.0% | Unchanged |
| US Bancorp | 127 | $0 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 426 | $0 | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 13,787 | $0 | 0.00% | 00.0% | Unchanged |
| Clearstead Advisors, LLC | 500 | $0 | 0.00% | 00.0% | Unchanged |
| Navellier & Associates Inc | 14,649 | $0 | 0.00% | 00.0% | Unchanged |
| California Public Employees Retirement System | 68,732 | $0 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 533 | $0 | 0.00% | 00.0% | Unchanged |
| Assetmark, Inc | 14 | $0 | 0.00% | 00.0% | Unchanged |
| Transamerica Financial Advisors, Inc. | 2 | $0 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 424 | $0 | 0.00% | 00.0% | Unchanged |
| Spark Investment Management LLC | 29,100 | $0 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 1,362 | $0 | 0.00% | 00.0% | Unchanged |
| EverSource Wealth Advisors, LLC | 4 | $0 | 0.00% | 00.0% | Unchanged |
| Sofos Investments, Inc. | 988 | – | – | +988 | New |
| OrbiMed Advisors LLC | 2,718,735 | – | – | 00.0% | Unchanged |